Health X Platform Ltd · NSE:HEALTHX
Health X Platform — Sastasundar Ventures — Investor Presentation (July 2023)
27 slides from Health X Platform's investor presentation, Jul 18, 2023
Slide 1: Regulation 30 intimation letter to stock exchanges
SASTASUNDAR VENTURES LIMITED Azimganj House, 2nd floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata – 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335 Email: info@sastasundar.com; Website: www.sastasundarventures.com CIN: L65993WB1989PLC047002 Date: 18-07-2023 To To Th
Slide 2: Investor Presentation July 2023
“Digital Platform of Pharma Supply Chain and Diagnostic providing access of quality healthcare for all” Investor Presentation July 2023
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sastasundar Ventures Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Opportunity to transform lives in the digital age
In this digital age, we have an opportunity to transform the lives of people in ways that were hard to imagine in the past. I see technology as a means of empowerment and as a tool that bridges the distance between hope and opportunity in this digital age. Shri Narendra Modi Hon’ble Prime Minister o
Slide 5: Management Commentary
Management Commentary Dear Shareholders, We are pleased to announce that our revenue from operations grew by 66.4% for FY 2022-23 and the Gross Margin has improved to 7.4% with continuous focus on cost optimisation, process improvement and digital technology. During the quarter ended March 2023, the
Slide 6: Significant Play in Indian ePharma & Pharma eDistribution
Significant Play in Indian ePharma & Pharma eDistribution – High Growth Sectors • Strategic Partnership with Flipkart ePharma • Market size US$345 mn in 2021 1 • To grow at CAGR of 22% • eB2B platform distributing pharma and other healthcare Indian Pharma Market (IPM) products to Pharmacies & other
Slide 7: Digital Platform of Healthcare
Digital Platform of Healthcare B2B Platform B2C Platform Pharmaceutials Diagnostic Pharmacy and & Other Services Wellness Healthcare Products 6
Slide 8: Growing Platform in ePharma
Growing Platform in ePharma Strategic partnership built on strong capabilities 75.10% 24.90% stake stake • Large consumer base • Most efficient supply chain & fulfilment capabilities • Established consumer tech capabilities • Direct procurement relationship with 250+ Pharma Companies • Huge brand pa
Slide 9: Pharma eDistribution – Digital Supply Chain of Pharmaceuticals
Pharma eDistribution – Digital Supply Chain of Pharmaceuticals & Other Healthcare Products • Digital Supply Chain poised to transform the Indian Pharma distribution benefiting everyone with Pharma Companies major beneficiary • Improved Business Forecasting Digital supply chain can lower • Inventory
Slide 10: Structural Shift – Consolidation on way in Indian Pharma Distribution
Structural Shift – Consolidation on way in Indian Pharma Distribution Pharmaceutical wholesaling/distribution is highly consolidated industry in most of the developed countries (period last 2 to 3 decades). India to witness similar consolidation in Pharmaceutical In USA, 92% of the market is with 3
Slide 11: Benefitting Pharma & FMCG Cos.
Benefitting Pharma & FMCG Cos. • End to End tracking of Inventory up to Retailers with real time data • Better managed inventory leading to reduced return of expired stocks • Better production and distribution planning • New drugs can be introduced faster • Huge scope for Pharma Companies for their
Slide 12: Benefitting Retailers - Transforming Economics & Lives of Retailers
Benefitting Retailers - Transforming Economics & Lives of Retailers Traditional Distributors Benefits to Retailers • Full visibility of Inventory online • Reduction of Inventory Lead Time • Sourcing from Multiple Distributors • 100% fulfilment • Lower Working Capital requirement • Fulfilment gaps •
Slide 13: Empowering Retailers – One Stop eProcurement Solution
Empowering Retailers – One Stop eProcurement Solution Widest Availability and 100% Genuine High Margins with Fulfilment of Products Products Transparent Pricing (65000+ Products) Automated Procurement Timely Delivery Clear Return Policy 12
Slide 14: Snapshot
Snapshot Genu Path Labs, an NABL ACCREDITED LAB, where everything revolves around Meticulous Assay of Quality Evidence. Highly experienced Clinical Team, Advanced High End Lab Equipment, Stringent Quality Norms – EQAS, ILC, Strong Process Control (QuaGenLR) – we employ all of these at Genu 35+ Sampl
Slide 15: GENU Health app - Under making of Powerful Health Solutions
GENU Health app - Under making of Powerful Health Solutions • Direct service to the consumers from Genu Path Labs as D2C Brand offering diagnostic services with seamless integration of technology • Centred around preventive care, diagnostic services, management of surgery and hospital care, heath/di
Slide 16: Sastasundar Group – Value Proposition
Sastasundar Group – Value Proposition • Best in class Customer Experience driven by Value Pricing, Quality and Tech • Clear visibility of high growth with EBITDA + model • Capital efficient with high ROCE • Strong MOAT ⁻ Established Business Technology with highly efficient supply chain ⁻ Managing 1
Slide 17: Experienced Board of Directors
Experienced Board of Directors FCA, FCS and FCM by education and has an experience of FCA by education and is a seasoned entrepreneur with more than 20 years working as an entrepreneur and a more than 20 years of demonstrated experience in social worker. scaling businesses from scratch. Areas
Slide 18: Q4 & FY23 Key Financial Highlights
Q4 & FY23 Key Financial Highlights Revenue from Operations Gross Profit EBITDA 6.1% 7.6% 6.5% 7.4% -12.2% -4.1% -9.2% -4.5% +88.9% +66.4% -33.7% -18.0% 1,036.9 76.5 -12.8 623.0 +147.9% 40.5 -19.3 +97.7% 311.5 23.8 157.6 9.6 -46.8 Q4FY22 Q4FY23 FY22 FY23 Q4FY22 Q4FY23 FY22 FY23 -57.1 Q4FY22 Q4FY23 FY
Slide 19: Q4 & FY23 Consolidated Profit & Loss Statement
Q4 & FY23 Consolidated Profit & Loss Statement Q4 FY22 Q3 FY23 FY22 Particulars (Rs. Crs) Q4 FY23 Y-o-Y Q-o-Q FY23 Y-o-Y (Restated) (Restated) (Restated) Revenue from Operations 311.5 157.6 97.7% 279.8 11.3% 1,036.9 623.0 66.4% Cost of Materials Consumed 287.7 148.0 258.3 960.4 582.5 Gross Profit 23
Slide 20: Consolidated Balance Sheet
Consolidated Balance Sheet Mar-22 Mar-22 Equity & Liabilities (Rs. Crs) Mar-23 Assets (Rs. Crs) Mar-23 (Restated) (Restated) Equity Share Capital 31.8 31.8 Property, Plant and Equipment 68.1 57.2 Capital Work-in-Progress 1.0 0.4 Other Equity# 961.7 1,062.4 Intangibles Assets 0.1 0.1 Total Equity 993
Slide 21: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. Crs) Mar-23 Mar-22 Cash Flow from Operating Activities Profit before Tax (122.3) 1,109.5 Adjustment for Non-Operating Items 84.0 (1,151.0) Operating Profit before Working Capital Changes (38.3) (41.5) Changes in Working Capital (70.2) (52.7) Cash Gen
Slide 22: Annual Financial Highlights
Annual Financial Highlights Rs. In Crs Revenue from Operations Gross Profit Q4 4.5% 8.8% 6.5% 7.4% Q3 169% +353% Q2 1,037 77 Q1 312 24 622 48 540 280 11 41 158 22 132 10 385 12 141 8 116 134 254 17 19 155 13 10 103 140 5 92 4 134 169 191 5 12 13 12 74 3 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Gross
Slide 23: Historical Consolidated Profit & Loss Statement
Historical Consolidated Profit & Loss Statement Particulars (Rs. Crs) Mar-23 Mar-22 (Restated) Mar-21 Mar-20 Mar-19 Revenue from Operations 1,036.9 623.0 540.0 384.0 215.6 Cost of Materials Consumed 960.4 582.5 492.5 366.9 199.5 Gross Profit 76.5 40.5 47.5 17.1 16.1 GP % 7.4% 6.5% 8.8% 4.5% 7.5% Emp
Slide 24: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Mar-22 Mar-22 Equity & Liabilities (Rs. Crs) Mar-23 Mar-21 Mar-20 Mar-19 Assets (Rs. Crs) Mar-23 Mar-21 Mar-20 Mar-19 (Restated) (Restated) Equity Share Capital 31.8 31.8 31.8 31.8 31.8 Property, Plant and Equipment 68.1 57.2 57.3 60.2 62.7 Other Equity # 961.7
Slide 25: Historical Consolidated Cash Flow Statement
Historical Consolidated Cash Flow Statement Particulars (Rs. Crs) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Cash Flow from Operating Activities Profit before Tax (122.3) 1,109.5 (16.4) (57.6) (41.8) Adjustment for Non-Operating Items 84.0 (1,151.0) (3.2) 4.8 7.8 Operating Profit before Working Capital Chan
Slide 26: 'Being Genuine' is Our Core Value 'Being Child' is Our Culture
‘Being Genuine’ is Our Core Value ‘Being Child’ is Our Culture 25
Slide 27: Thank You
Company: Thank You SastaSundar Ventures Limited CIN: L65993WB1989PLC047002 Mr. Pratap Singh – Company Secretary Email Id : investors@sastasundar.com www.sastasundarventures.com Investor Relations Partner: Orient Capital (a division of Link Group) Ronak Jain Irfan Raeen Ronak.jain@linkintime.co.in Ir
Sastasundar Ventures — Investor Presentation (July 2023) on 6ix